Cargando…

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Facchinetti, Fabrizio, Civelli, Maurizio, Singh, Dave, Papi, Alberto, Emirova, Aida, Govoni, Mirco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650159/ https://www.ncbi.nlm.nih.gov/pubmed/34887752 http://dx.doi.org/10.3389/fphar.2021.740803

Ejemplares similares

The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils
por: Schioppa, Tiziana, et al.
Publicado: (2022)

The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation
por: Nguyen, Hoang Oanh, et al.
Publicado: (2022)

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
por: Nguyen, Hoang Oanh, et al.
Publicado: (2022)

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
por: Singh, Dave, et al.
Publicado: (2020)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020)

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
por: Govoni, Mirco, et al.
Publicado: (2020)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum
por: Singh, Dave, et al.
Publicado: (2020)

A Novel Processing-Free Method for RNAseq Analysis of Spontaneous Sputum in Chronic Obstructive Pulmonary Disease
por: Ricci, Francesca, et al.
Publicado: (2021)

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation
por: Vang, Amanda G., et al.
Publicado: (2016)

Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications
por: Agusti, Alvar, et al.
Publicado: (2021)

Self-Reported Overall Adherence and Correct Inhalation Technique Discordance in Chronic Obstructive Pulmonary Disease Population
por: Hendrychova, Tereza, et al.
Publicado: (2022)

PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis
por: Noel, Sabrina, et al.
Publicado: (2012)

Effect of pulmonary rehabilitation on heart rate recovery in adult individuals with asthma or chronic obstructive pulmonary disease
por: Zampogna, Elisabetta, et al.
Publicado: (2022)

PDE4 and PDE5 regulate cyclic nucleotide contents and relaxing effects on carbachol-induced contraction in the bovine abomasum
por: KANEDA, Takeharu, et al.
Publicado: (2014)

Baicalein Ameliorates Aβ-Induced Memory Deficits and Neuronal Atrophy via Inhibition of PDE2 and PDE4
por: Shi, Jing, et al.
Publicado: (2021)

An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease
por: Çakmaklı, Seçil, et al.
Publicado: (2023)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2022)

Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors
por: De Toni, Luca, et al.
Publicado: (2018)

Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
por: Chen, Hong, et al.
Publicado: (2021)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2023)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Asthma progression and mortality: the role of inhaled corticosteroids
por: O'Byrne, Paul, et al.
Publicado: (2019)

Pulmonary Rehabilitation and Asthma
por: Zampogna, Elisabetta, et al.
Publicado: (2020)

Breathing Out Completely Before Inhalation: The Most Problematic Step in Application Technique in Patients With Non-Mild Chronic Obstructive Pulmonary Disease
por: Vytrisalova, Magda, et al.
Publicado: (2019)

Use of a Fission Yeast Platform to Identify and Characterize Small Molecule PDE Inhibitors
por: Hoffman, Charles S.
Publicado: (2022)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

In vitro neutrophil migration is associated with inhaled corticosteroid treatment and serum cytokines in pediatric asthma
por: Lemmel, Solveig, et al.
Publicado: (2022)

The Nurse Practitioners' Perspective on Inhaler Education in Asthma and Chronic Obstructive Pulmonary Disease
por: Scullion, Jane
Publicado: (2018)

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective
por: Chan, Amy H. Y., et al.
Publicado: (2021)

The regulatory role of PDE4B in the progression of inflammatory function study
por: Su, Yue, et al.
Publicado: (2022)

Respiratory Adherence Care Enhancer Questionnaire: Identifying Self-Management Barriers of Inhalation Corticosteroids in Asthma
por: Visser, Claire D., et al.
Publicado: (2021)

Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma
por: Hua, Jian-lan, et al.
Publicado: (2021)

Asthma Therapies on Pulmonary Tuberculosis Pneumonia in Predominant Bronchiectasis–Asthma Combination
por: Yeh, Jun-Jun, et al.
Publicado: (2022)

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(®) Dry Powder Inhaler
por: Prime, David, et al.
Publicado: (2015)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ipr8iskch6fp0v96tdl1tuosd